Kymera Therapeutics is a clinical-stage biotech developing targeted protein degraders—small molecules designed to eliminate disease-causing proteins rather than merely blocking them. Its platform applies this modality mainly in immunology and oncology, aiming at targets that have been hard to drug with conventional inhibitors. The company partners and advances programs for patients with serious immune-mediated and cancer indications.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 11.5 | — | -76.6 | — |
| Q3 2025 | 2.8 | — | -82.2 | — |
| Q4 2025 | 2.9 | — | -87 | — |
| Q1 2026 | 34.4 | — | -69.2 | — |
| Q2 2026 | 65 | 466.4% | -61.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Caris Life Sciences, Inc. (CAI), Cytokinetics, Incorporated (CYTK), Chord Energy Corporation (CHRD), Hut 8 Corp. (HUT), Bruker Corporation (BRKR), Protagonist Therapeutics, Inc. (PTGX)